Targeting specific immune responses in acute myeloid leukemia treatment
Minor Histocompatibility Antigen T Cell Targeting in Acute Myeloid Leukemia
This study is looking at how targeting specific proteins in your body can help improve treatment for people with acute myeloid leukemia (AML) who are getting stem cell transplants, aiming to make the treatment more effective against leukemia while reducing side effects.
Quick facts
| Grant type | Fellowship grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Univ of North Carolina Chapel Hill NIH-funded |
| Lab location | 1 site (Chapel Hill, United States) |
| Project ID | NIH-10897335 on NIH RePORTER |
What this research studies
This research investigates how targeting minor histocompatibility antigens (mHAs) can improve outcomes for patients with acute myeloid leukemia (AML) undergoing allogeneic stem cell transplantation (alloSCT). The approach focuses on enhancing the graft versus leukemia (GvL) effect, where donor T cells attack leukemia cells while minimizing the risk of graft versus host disease (GvHD), a serious side effect. By understanding the differences in mHAs between donors and recipients, the study aims to refine treatment strategies that could lead to better survival rates for AML patients. The methodology includes analyzing immune responses and the genetic factors involved in these interactions.
Who could benefit from this research
Good fit: Ideal candidates for this research are patients diagnosed with acute myeloid leukemia who are considering or undergoing allogeneic stem cell transplantation.
Not a fit: Patients with acute myeloid leukemia who are not eligible for allogeneic stem cell transplantation may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to more effective and safer treatments for patients with acute myeloid leukemia.
How similar studies have performed: Previous research has shown promising results in targeting minor histocompatibility antigens to improve outcomes in stem cell transplantation, indicating that this approach has potential for success.
Where this research is happening
Chapel Hill, United States
- Univ of North Carolina Chapel Hill — Chapel Hill, United States (Active)
Researchers
- Principal investigator: Olsen, Kelly Shea — Univ of North Carolina Chapel Hill
- Study coordinator: Olsen, Kelly Shea
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.